Nurix Began Clinical Trial of Bexobrutideg Combo
The Phase 1b/2 trial evaluates a BTK degrader combined with BCL2 inhibition for leukemia patients.
Updated on Oct. 7, 2026 in Biotech
Live Poll
Do you believe pharmaceutical companies should prioritize developing combination drug therapies for cancer treatment?
Nurix Therapeutics has enrolled the first patient in a Phase 1b/2 clinical study to test the efficacy of bexobrutideg in combination with venetoclax. This research-stage effort, conducted in collaboration with Roche, targets patients with chronic lymphocytic leukemia.
Why it matters
Combination therapies represent a critical trajectory in oncology, as researchers seek to address drug resistance in chronic lymphocytic leukemia. This trial aims to determine if layering a novel degrader on top of standard care improves therapeutic outcomes.
The study evaluates the combination of bexobrutideg, an investigational oral Bruton's tyrosine kinase (BTK) degrader, with venetoclax, a BCL2 inhibitor. Researchers are assessing the safety, tolerability, and clinical activity of this regimen in patients with chronic lymphocytic leukemia.
The players
Nurix Therapeutics
A Brisbane-based biotechnology company focused on the discovery and development of targeted protein degradation therapeutics.
Roche
A multinational healthcare company with a robust portfolio in oncology and a major partner in clinical research collaborations.
The details
Bexobrutideg works by inducing the degradation of Bruton's tyrosine kinase, a signaling protein that supports the survival of malignant B-cells. By combining this with venetoclax—a therapy that blocks the BCL2 protein, which cancer cells rely on to evade programmed cell death—the study attempts to simultaneously target two distinct survival pathways. The research includes the potential to add selected antibodies to the regimen and may expand into broader B-cell malignancy applications.
Timeline
October 6, 2026: The first patient was enrolled in the NX-5948-203 Phase 1b/2 study.
The Tech Race
The trial places Nurix in direct competition with other pharmaceutical firms racing to develop the next generation of targeted protein degradation agents. This study serves as a critical milestone to inform registrational development strategies against established chronic lymphocytic leukemia therapies.
This development is currently limited to the clinical research setting and is not available for general patient use. Future availability depends on successful safety and efficacy data from this Phase 1b/2 study and subsequent regulatory review.
The takeaway
The industry is increasingly shifting toward combination regimens to overcome limitations in current B-cell malignancy treatments. Observers should monitor future data releases from the NX-5948-203 study to see if the combination demonstrates superior clinical activity.
Further reading
For broader context on current clinical advancements, see Biotech.
More information
You can track the trial progress through the clinical trials information lookup.
Live Poll
Do you believe pharmaceutical companies should prioritize developing combination drug therapies for cancer treatment?
